Neural mediation of vasoactive intestinal polypeptide inhibitory effect on jejunal alanine absorption.
It was recently shown that vasoactive intestinal polypeptide (VIP) inhibits rat jejunal alanine absorption, an effect that was significantly reduced by vagotomy. This study assesses the role of capsaicin-sensitive primary afferents (CSPA) and the myenteric plexus in the inhibition of rat jejunal alanine absorption by VIP. Continuous intravenous infusion of VIP (11.2 ng . kg-1 . min-1) reduced alanine absorption by 60% in sham control rats and by 20% in rats neonatally treated with capsaicin (P < 0.01). In in vitro experiments, VIP decreased alanine uptake by jejunal strips isolated from sham control rats in a dose-dependent manner. In the presence of 40 nM VIP, alanine uptake by full-thickness jejunal strips was reduced by 54% in sham control rats and by 25% in rats neonatally treated with capsaicin (P < 0.001). On the other hand, VIP reduced alanine uptake by mucosal scrapings by 25% in sham rats compared with 9% reduction in neonatally treated rats. Chemical ablation of the extrinsic innervation and jejunal myenteric plexuses by pretreatment with benzalkonium chloride significantly (P < 0.001) reduced basal alanine absorption and the inhibitory effect of VIP. Moreover, incubation of intestinal strips with tetrodotoxin and atropine reduced significantly (P < 0.05) the inhibitory effect of VIP on alanine absorption. These data suggest that VIP exerts its inhibitory effect on alanine absorption through the CSPA fibers and the myenteric plexus. The neuronal circuitry of this inhibitory process may involve cholinergic muscarinic mechanisms.
Departments of Physiology, Human Morphology, and Internal Medicine, American University of Beirut, Beirut, Lebanon.
K A
KA
Barada
N E
NE
Saadé
S F
SF
Atweh
C F
CF
Nassar
D000344:Afferent Pathways / Q000187:drug effects / Q000502:physiology*; D000409:Alanine / Q000378:metabolism*; D000818:Animals; D002211:Capsaicin / Q000031:analogs & derivatives / Q000494:pharmacology*; D005260:Female; D066298:In Vitro Techniques; D007262:Infusions, Intravenous; D007408:Intestinal Absorption / Q000187:drug effects / Q000502:physiology*; D007413:Intestinal Mucosa / Q000187:drug effects / Q000502:physiology*; D007583:Jejunum / Q000187:drug effects / Q000294:innervation / Q000502:physiology*; D007700:Kinetics; D008297:Male; D009412:Nerve Fibers / Q000187:drug effects / Q000502:physiology; D051381:Rats; D017207:Rats, Sprague-Dawley; D014660:Vasoactive Intestinal Peptide / Q000008:administration & dosage / Q000494:pharmacology* / Q000502:physiology
D014660:Vasoactive Intestinal Peptide; D000409:Alanine; D002211:Capsaicin; C012906:dihydrocapsaicin